The TGA has approved
GlaxoSmithKline’s combination
of Mekinist (trametinib) and
Tafinlar(dabrafenib) for the
treatment of patients with
BRAF V600 mutation positive
unresectable Stage III or metastatic
(stage IV) melanoma, as well
as a monotherapy where BRAF
inhibitors could not be used.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Mar 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.